Annual Operating Profit
$9.82 M
+$6.78 M+223.38%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual operaing income is currently $9.82 million, with the most recent change of +$6.78 million (+223.38%) on 31 December 2023. During the last 3 years, it has fallen by -$10.56 million (-51.82%). LGND annual operating profit is now -94.00% below its all-time high of $163.73 million, reached on 31 December 2018.LGND Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Profit
$10.96 M
+$3.56 M+48.22%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly operating income is currently $10.96 million, with the most recent change of +$3.56 million (+48.22%) on 30 September 2024. Over the past year, it has increased by +$10.00 million (+1044.72%). LGND quarterly operating profit is now -84.39% below its all-time high of $70.17 million, reached on 30 June 2018.LGND Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Operating Profit
$17.98 M
+$10.00 M+125.32%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated TTM operating income is currently $17.98 million, with the most recent change of +$10.00 million (+125.32%) on 30 September 2024. Over the past year, it has increased by +$24.90 million (+359.77%). LGND TTM operating profit is now -89.02% below its all-time high of $163.73 million, reached on 31 December 2018.LGND TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND Operating Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +223.4% | +1044.7% | +359.8% |
| 3 y3 years | -51.8% | -30.3% | -75.0% |
| 5 y5 years | -94.0% | +312.4% | -52.2% |
LGND Operating Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -90.5% | +223.4% | -70.9% | +154.5% | -82.7% | +359.8% |
| 5 y | 5 years | -94.0% | +271.7% | -76.0% | +154.5% | -82.7% | +214.7% |
| alltime | all time | -94.0% | +112.6% | -84.4% | +124.8% | -89.0% | +118.3% |
Ligand Pharmaceuticals Incorporated Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $10.96 M(+48.2%) | $17.98 M(+125.3%) |
| June 2024 | - | $7.39 M(+147.4%) | $7.98 M(-671.5%) |
| Mar 2024 | - | $2.99 M(-189.0%) | -$1.40 M(-114.2%) |
| Dec 2023 | $9.82 M(+223.4%) | -$3.36 M(-450.9%) | $9.82 M(-241.9%) |
| Sept 2023 | - | $957.00 K(-148.3%) | -$6.92 M(-255.0%) |
| June 2023 | - | -$1.98 M(-114.0%) | $4.46 M(-70.5%) |
| Mar 2023 | - | $14.21 M(-170.7%) | $15.11 M(+397.5%) |
| Dec 2022 | $3.04 M(-97.1%) | -$20.10 M(-262.9%) | $3.04 M(-95.0%) |
| Sept 2022 | - | $12.34 M(+42.5%) | $60.83 M(-5.2%) |
| June 2022 | - | $8.66 M(+306.1%) | $64.19 M(-36.6%) |
| Mar 2022 | - | $2.13 M(-94.3%) | $101.27 M(-2.5%) |
| Dec 2021 | $103.85 M(+409.4%) | $37.69 M(+140.0%) | $103.85 M(+44.4%) |
| Sept 2021 | - | $15.71 M(-65.7%) | $71.91 M(+19.9%) |
| June 2021 | - | $45.74 M(+870.1%) | $59.95 M(+181.3%) |
| Mar 2021 | - | $4.71 M(-18.0%) | $21.31 M(+4.5%) |
| Dec 2020 | $20.39 M(-456.3%) | $5.75 M(+53.5%) | $20.39 M(+357.5%) |
| Sept 2020 | - | $3.75 M(-47.2%) | $4.46 M(-200.2%) |
| June 2020 | - | $7.10 M(+87.4%) | -$4.45 M(-71.6%) |
| Mar 2020 | - | $3.79 M(-137.2%) | -$15.68 M(+174.1%) |
| Dec 2019 | -$5.72 M(-103.5%) | -$10.18 M(+97.3%) | -$5.72 M(-115.2%) |
| Sept 2019 | - | -$5.16 M(+24.9%) | $37.61 M(-43.1%) |
| June 2019 | - | -$4.13 M(-130.0%) | $66.13 M(-52.9%) |
| Mar 2019 | - | $13.75 M(-58.5%) | $140.43 M(-14.2%) |
| Dec 2018 | $163.73 M(+140.5%) | $33.15 M(+41.9%) | $163.73 M(+3.0%) |
| Sept 2018 | - | $23.36 M(-66.7%) | $158.93 M(+4.5%) |
| June 2018 | - | $70.17 M(+89.5%) | $152.06 M(+60.2%) |
| Mar 2018 | - | $37.04 M(+30.7%) | $94.90 M(+39.4%) |
| Dec 2017 | $68.08 M(+55.1%) | $28.35 M(+71.9%) | $68.07 M(+15.2%) |
| Sept 2017 | - | $16.49 M(+26.7%) | $59.08 M(+22.9%) |
| June 2017 | - | $13.02 M(+27.4%) | $48.05 M(+23.2%) |
| Mar 2017 | - | $10.22 M(-47.2%) | $39.01 M(-11.1%) |
| Dec 2016 | $43.88 M(+60.6%) | $19.36 M(+254.1%) | $43.89 M(+26.3%) |
| Sept 2016 | - | $5.47 M(+37.7%) | $34.76 M(-9.1%) |
| June 2016 | - | $3.97 M(-73.7%) | $38.24 M(-1.6%) |
| Mar 2016 | - | $15.10 M(+47.6%) | $38.85 M(+42.2%) |
| Dec 2015 | $27.33 M(+32.0%) | $10.23 M(+14.4%) | $27.33 M(+0.1%) |
| Sept 2015 | - | $8.94 M(+95.1%) | $27.30 M(+23.7%) |
| June 2015 | - | $4.58 M(+28.3%) | $22.07 M(+16.3%) |
| Mar 2015 | - | $3.57 M(-65.0%) | $18.98 M(-8.4%) |
| Dec 2014 | $20.71 M(+29.6%) | $10.20 M(+174.6%) | $20.71 M(+20.8%) |
| Sept 2014 | - | $3.71 M(+148.6%) | $17.14 M(+2.5%) |
| June 2014 | - | $1.49 M(-71.8%) | $16.72 M(-3.2%) |
| Mar 2014 | - | $5.30 M(-20.0%) | $17.27 M(+8.0%) |
| Dec 2013 | $15.98 M(+1215.5%) | $6.63 M(+101.0%) | $15.98 M(+14.3%) |
| Sept 2013 | - | $3.30 M(+61.8%) | $13.98 M(+48.4%) |
| June 2013 | - | $2.04 M(-49.3%) | $9.43 M(+57.4%) |
| Mar 2013 | - | $4.02 M(-13.1%) | $5.99 M(+392.8%) |
| Dec 2012 | $1.22 M(+378.3%) | $4.63 M(-467.1%) | $1.22 M(-21.3%) |
| Sept 2012 | - | -$1.26 M(-10.0%) | $1.54 M(+9.5%) |
| June 2012 | - | -$1.40 M(+86.3%) | $1.41 M(-9.6%) |
| Mar 2012 | - | -$752.00 K(-115.2%) | $1.56 M(+521.1%) |
| Dec 2011 | $254.00 K(-102.2%) | $4.96 M(-455.4%) | $251.00 K(-97.1%) |
| Sept 2011 | - | -$1.40 M(+11.4%) | $8.55 M(-239.0%) |
| June 2011 | - | -$1.25 M(-39.2%) | -$6.15 M(-31.3%) |
| Mar 2011 | - | -$2.06 M(-115.5%) | -$8.95 M(-21.1%) |
| Dec 2010 | -$11.36 M(-63.8%) | $13.26 M(-182.4%) | -$11.35 M(-74.9%) |
| Sept 2010 | - | -$16.10 M(+297.2%) | -$45.20 M(+59.6%) |
| June 2010 | - | -$4.05 M(-8.9%) | -$28.33 M(-0.6%) |
| Mar 2010 | - | -$4.45 M(-78.4%) | -$28.49 M(-10.5%) |
| Dec 2009 | -$31.38 M | -$20.60 M(-2761.0%) | -$31.85 M(+118.1%) |
| Sept 2009 | - | $774.00 K(-118.4%) | -$14.60 M(-32.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$4.22 M(-46.0%) | -$21.73 M(-6.1%) |
| Mar 2009 | - | -$7.81 M(+132.9%) | -$23.15 M(-16.5%) |
| Dec 2008 | -$27.24 M(-56.2%) | -$3.35 M(-47.2%) | -$27.73 M(-19.3%) |
| Sept 2008 | - | -$6.36 M(+12.8%) | -$34.38 M(-6.4%) |
| June 2008 | - | -$5.63 M(-54.5%) | -$36.75 M(-19.2%) |
| Mar 2008 | - | -$12.39 M(+23.8%) | -$45.49 M(-26.8%) |
| Dec 2007 | -$62.14 M(-20.4%) | -$10.01 M(+14.7%) | -$62.14 M(-17.6%) |
| Sept 2007 | - | -$8.72 M(-39.3%) | -$75.39 M(-15.4%) |
| June 2007 | - | -$14.37 M(-50.5%) | -$89.12 M(-4.0%) |
| Mar 2007 | - | -$29.04 M(+24.9%) | -$92.81 M(+18.9%) |
| Dec 2006 | -$78.08 M(+79.0%) | -$23.26 M(+3.6%) | -$78.08 M(-0.4%) |
| Sept 2006 | - | -$22.45 M(+24.3%) | -$78.38 M(+29.5%) |
| June 2006 | - | -$18.06 M(+26.2%) | -$60.52 M(+23.6%) |
| Mar 2006 | - | -$14.31 M(-39.2%) | -$48.97 M(-2.9%) |
| Dec 2005 | -$43.63 M(+183.7%) | -$23.56 M(+413.4%) | -$50.42 M(-535.9%) |
| Sept 2005 | - | -$4.59 M(-29.5%) | $11.57 M(+1995.8%) |
| June 2005 | - | -$6.51 M(-58.7%) | $552.00 K(-104.6%) |
| Mar 2005 | - | -$15.77 M(-141.0%) | -$12.07 M(-21.5%) |
| Dec 2004 | -$15.38 M(-79.2%) | $38.44 M(-346.3%) | -$15.38 M(-84.3%) |
| Sept 2004 | - | -$15.61 M(-18.4%) | -$98.00 M(+8.2%) |
| June 2004 | - | -$19.13 M(+0.2%) | -$90.59 M(+12.5%) |
| Mar 2004 | - | -$19.08 M(-56.8%) | -$80.54 M(+8.8%) |
| Dec 2003 | -$74.02 M(+68.8%) | -$44.19 M(+439.3%) | -$74.02 M(+34.4%) |
| Sept 2003 | - | -$8.19 M(-9.7%) | -$55.07 M(+2.6%) |
| June 2003 | - | -$9.07 M(-27.8%) | -$53.66 M(-0.7%) |
| Mar 2003 | - | -$12.56 M(-50.2%) | -$54.07 M(+23.3%) |
| Dec 2002 | -$43.85 M(+89.5%) | -$25.25 M(+272.0%) | -$43.85 M(+107.3%) |
| Sept 2002 | - | -$6.79 M(-28.4%) | -$21.16 M(+11.8%) |
| June 2002 | - | -$9.47 M(+303.7%) | -$18.93 M(+10.6%) |
| Mar 2002 | - | -$2.35 M(-7.9%) | -$17.12 M(-26.0%) |
| Dec 2001 | -$23.14 M(-49.6%) | -$2.55 M(-44.1%) | -$23.14 M(-22.9%) |
| Sept 2001 | - | -$4.56 M(-40.5%) | -$30.00 M(-16.4%) |
| June 2001 | - | -$7.67 M(-8.4%) | -$35.88 M(-14.1%) |
| Mar 2001 | - | -$8.37 M(-11.1%) | -$41.79 M(-7.1%) |
| Dec 2000 | -$45.88 M(-25.1%) | -$9.41 M(-9.8%) | -$44.98 M(-13.9%) |
| Sept 2000 | - | -$10.44 M(-23.1%) | -$52.23 M(-8.3%) |
| June 2000 | - | -$13.58 M(+17.5%) | -$56.93 M(-5.4%) |
| Mar 2000 | - | -$11.55 M(-30.6%) | -$60.15 M(-1.9%) |
| Dec 1999 | -$61.29 M(-11.9%) | -$16.66 M(+10.1%) | -$61.30 M(-10.6%) |
| Sept 1999 | - | -$15.13 M(-9.9%) | -$68.53 M(-2.5%) |
| June 1999 | - | -$16.80 M(+32.3%) | -$70.30 M(+0.9%) |
| Mar 1999 | - | -$12.70 M(-46.9%) | -$69.70 M(+0.1%) |
| Dec 1998 | -$69.60 M(+126.0%) | -$23.90 M(+41.4%) | -$69.60 M(+46.2%) |
| Sept 1998 | - | -$16.90 M(+4.3%) | -$47.60 M(+16.1%) |
| June 1998 | - | -$16.20 M(+28.6%) | -$41.00 M(+19.9%) |
| Mar 1998 | - | -$12.60 M(+563.2%) | -$34.20 M(+11.4%) |
| Dec 1997 | -$30.80 M(-6.4%) | -$1.90 M(-81.6%) | -$30.70 M(-22.1%) |
| Sept 1997 | - | -$10.30 M(+9.6%) | -$39.40 M(+9.1%) |
| June 1997 | - | -$9.40 M(+3.3%) | -$36.10 M(+1.4%) |
| Mar 1997 | - | -$9.10 M(-14.2%) | -$35.60 M(+9.2%) |
| Dec 1996 | -$32.90 M(+32.1%) | -$10.60 M(+51.4%) | -$32.60 M(+10.9%) |
| Sept 1996 | - | -$7.00 M(-21.3%) | -$29.40 M(-2.3%) |
| June 1996 | - | -$8.90 M(+45.9%) | -$30.10 M(+90.5%) |
| Mar 1996 | - | -$6.10 M(-17.6%) | -$15.80 M(+14.5%) |
| Dec 1995 | -$24.90 M(+19.1%) | -$7.40 M(-3.9%) | -$13.80 M(+23.2%) |
| Sept 1995 | - | -$7.70 M(-242.6%) | -$11.20 M(+34.9%) |
| June 1995 | - | $5.40 M(-231.7%) | -$8.30 M(-57.2%) |
| Mar 1995 | - | -$4.10 M(-14.6%) | -$19.40 M(-7.2%) |
| Dec 1994 | -$20.90 M | -$4.80 M(0.0%) | -$20.90 M(+29.8%) |
| Sept 1994 | - | -$4.80 M(-15.8%) | -$16.10 M(+42.5%) |
| June 1994 | - | -$5.70 M(+1.8%) | -$11.30 M(+101.8%) |
| Mar 1994 | - | -$5.60 M | -$5.60 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual operaing income?
- What is the all time high annual operating profit for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual operating profit year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly operating income?
- What is the all time high quarterly operating profit for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly operating profit year-on-year change?
- What is Ligand Pharmaceuticals Incorporated TTM operating income?
- What is the all time high TTM operating profit for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated TTM operating profit year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual operaing income?
The current annual operating profit of LGND is $9.82 M
What is the all time high annual operating profit for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual operaing income is $163.73 M
What is Ligand Pharmaceuticals Incorporated annual operating profit year-on-year change?
Over the past year, LGND annual operaing income has changed by +$6.78 M (+223.38%)
What is Ligand Pharmaceuticals Incorporated quarterly operating income?
The current quarterly operating profit of LGND is $10.96 M
What is the all time high quarterly operating profit for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly operating income is $70.17 M
What is Ligand Pharmaceuticals Incorporated quarterly operating profit year-on-year change?
Over the past year, LGND quarterly operating income has changed by +$10.00 M (+1044.72%)
What is Ligand Pharmaceuticals Incorporated TTM operating income?
The current TTM operating profit of LGND is $17.98 M
What is the all time high TTM operating profit for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high TTM operating income is $163.73 M
What is Ligand Pharmaceuticals Incorporated TTM operating profit year-on-year change?
Over the past year, LGND TTM operating income has changed by +$24.90 M (+359.77%)